Free tool
FAERS Monitor: Nextstellis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214154 or its brand name (Nextstellis, Drospirenone, Estetrol). Reports on generic versions are filed under their own applications.
Reports
296
Serious
102
34% of reports
Hospitalization
29
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intermenstrual bleeding26
- heavy menstrual bleeding21
- headache16
- drug ineffective15
- dizziness13
- mood swings12
- off label use12
- nausea11
- product use in unapproved indication11
- migraine10
- suicidal ideation10
- weight increased10
- depression9
- menstruation irregular9
- alopecia8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 7 |
| 2022 | 75 |
| 2023 | 64 |
| 2024 | 28 |
| 2025 | 45 |
| 2026 | 77 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,863 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intermenstrual bleedingSignal | 26 | 332.1 | 229.9 | 8,219 |
| heavy menstrual bleedingSignal | 21 | 166.2 | 110.0 | 3,280 |
| mood swingsSignal | 12 | 26.8 | 15.4 | 273 |
| menstruation irregularSignal | 9 | 23.9 | 12.6 | 175 |
| suicidal ideationSignal | 10 | 7.8 | 4.2 | 53 |
| migraineSignal | 10 | 7.4 | 4.0 | 50 |
| weight increasedSignal | 10 | 3.2 | 1.7 | 13 |
| product use in unapproved indicationSignal | 11 | 3.2 | 1.8 | 14 |
| alopeciaSignal | 8 | 2.9 | 1.5 | 8 |
| depressionSignal | 9 | 2.8 | 1.5 | 9 |
| dizziness | 13 | 1.9 | 1.1 | 4 |
| headache | 16 | 1.8 | 1.1 | 5 |
| nausea | 11 | 1.0 | 0.6 | 0 |
| off label use | 12 | 1.0 | 0.6 | 0 |
| drug ineffective | 15 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.